Recursion reports Phase 2 REC-4881 data, new chair, Q3 results

Clinical data from an AI-driven drug pipeline is a key test of the discovery model.

Recursion Pharmaceuticals released Phase 2 REC-4881 trial data and appointed a new board chair alongside Q3 earnings and clinical updates, prompting investor analysis.

Domain

drug

Read it at Yahoo Finance Singapore →

Coverage: 3 sources, in order

1. 05 Nov 00:15 Yahoo Finance Singapore Read the article →
2. 05 Nov 00:49 Simply Wall St Read the article →
3. 05 Nov 08:16 Yahoo Finance Read the article →

← Front page